Xin Lang Cai Jing·2025-12-19 01:38Core Viewpoint - The announcement from Renfu Pharmaceutical Group Co., Ltd. regarding the receipt of an administrative penalty notice from the Hubei Securities Regulatory Bureau indicates that investors affected by information disclosure violations may have grounds for compensation claims [1][6]. Summary by Sections Administrative Penalty Notice - On December 12, 2024, Renfu Pharmaceutical (stock code: 600079) announced it received an administrative penalty notice from the Hubei Securities Regulatory Bureau [1][6]. Compensation Conditions - Investors who purchased ST Renfu shares between April 23, 2023, and October 24, 2024, and still held the shares at the close on October 24, 2024, may preliminarily qualify for compensation [2][8]. - The final scope of compensation will be determined by court rulings [2]. Required Documentation for Claims - Investors must prepare the following documents to support their claims: 1. Original stock transaction statement stamped by the brokerage, showing all trading records from the first purchase to the date of printing, including remaining shares for current holders [2][8]. 2. A photocopy of the investor's ID card, showing both sides [3]. 3. A securities account confirmation slip issued by the brokerage, detailing account information [4][9]. Legal Commentary - Lawyer Niu Bin from Shanghai Baiyue Law Firm stated that the conditions for compensation registration are based on the administrative penalty notice and do not constitute investment advice or guarantees regarding the outcome of claims [5][10].